Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Legend Biotech Corp ADR (LEGN)

Legend Biotech Corp ADR (LEGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

LEGN : 34.48 (+6.95%)
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

LEGN : 34.48 (+6.95%)
Oncology Experts Predict 2025 Will Be a Year of Breakthroughs in Treatment and Prevention

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – One of the largest and most advanced cancer research and treatment organizations in the USA, City of Hope,...

ONCY : 0.5982 (+4.03%)
GH : 43.80 (+2.79%)
LEGN : 34.48 (+6.95%)
PSNL : 3.41 (+7.91%)
GRAL : 29.69 (+12.38%)
ONC.TO : 0.84 (+6.33%)
Legend Biotech CEO to Present Company Updates at 43rd Annual J.P. Morgan Healthcare Conference

Legend Biotech's CEO will present company updates at the J.P. Morgan Healthcare Conference on January 14, 2025.Quiver AI SummaryLegend Biotech Corporation announced that CEO Ying Huang, Ph.D., will present...

LEGN : 34.48 (+6.95%)
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

LEGN : 34.48 (+6.95%)
Legend Biotech Reports 89% MRD Negativity in CARTITUDE-4 Study for CARVYKTI® in Multiple Myeloma After Three-Year Follow-Up

New data shows CARVYKTI® achieves 89% MRD negativity in multiple myeloma patients, significantly surpassing standard therapies.Quiver AI SummaryLegend Biotech has announced promising results from its...

LEGN : 34.48 (+6.95%)
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

LEGN : 34.48 (+6.95%)
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

LEGN : 34.48 (+6.95%)
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

LEGN : 34.48 (+6.95%)
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

LEGN : 34.48 (+6.95%)

Barchart Exclusives

Palantir Is a Frontrunner for Trump’s ‘Golden Dome.’ Should You Buy PLTR Stock Now?
Down 25% from all-time highs, Palantir stock trades at an expensive valuation in April 2025. Let's see if PLTR stock is a buy, sell, or hold, according to consensus estimates. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar